Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies-Reference-Cited by-同舟云学术

Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies

Published:2019-05-16 Issue:1 Volume:50 Page:54-65
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Simsek Melek¹^ORCID,Deben Debbie S.²,Horjus Carmen S.³,Bénard Melanie V.⁴,Lissenberg-Witte Birgit I.⁵,Buiter Hans J. C.⁶,van Luin Matthijs⁷,Seinen Margien L.⁴,Mulder Chris J. J.⁴,Wong Dennis R.²^ORCID,de Boer Nanne K. H.¹,van Bodegraven Adriaan A.⁴⁸^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology; Amsterdam UMC, Vrije Universiteit Amsterdam, AG&M Research Institute; Amsterdam The Netherlands

2. Department of Clinical Pharmacy, Clinical Pharmacology and Toxicology, Zuyderland Medical Centre; Sittard-Geleen-Heerlen; The Netherlands

3. Department of Gastroenterology and Hepatology; Rijnstate Hospital; Arnhem The Netherlands

4. Department of Gastroenterology and Hepatology; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam The Netherlands

5. Department of Epidemiology and Biostatistics; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam The Netherlands

6. Department of Clinical Pharmacology and Pharmacy; Amsterdam UMC, Vrije Universiteit Amsterdam; Amsterdam The Netherlands

7. Department of Clinical Pharmacology and Pharmacy; Rijnstate Hospital; Arnhem The Netherlands

8. Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK); Zuyderland Medical Centre, Sittard-Geleen-Heerlen; The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15280/fullpdf

Reference44 articles.

1. Current and emerging therapeutic targets for IBD;Neurath;Nat Rev Gastroenterol Hepatol,2017

2. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease;Lemaitre;JAMA,2017

3. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory bowel disease;Derijks;Clin Pharmacokinet,2018

4. Current and emerging drugs for the treatment of inflammatory bowel disease;Triantafillidis;Drug Des Devel Ther,2011

5. Optimization of conventional therapy in patients with IBD;Taylor;Nat Rev Gastroenterol Hepatol,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment;British Journal of Clinical Pharmacology;2024-08-25

2. Exploring the role of oxidative stress and the effect of N‐acetylcysteine in thiopurine‐induced liver injury in inflammatory bowel disease: A randomized crossover pilot study;Basic & Clinical Pharmacology & Toxicology;2024-01-29

3. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study;Therapeutic Advances in Gastroenterology;2024-01

4. Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease – A comprehensive narrative review;Digestive and Liver Disease;2023-12

5. Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency;Metabolites;2023-10-06